Breda Flood, President of the European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) will present the U-BIOPRED project at the “Applying open innovation to bring personalized medicine to new disease areas” workshop on March 20th.
Dr. Michael Goldman, Executive Director of the Innovation Medicines Initiative (IMI), invited Breda to provide a patient’s perspective and the “patient’s vision” of U-BIOPRED.
Breda will speak at the start of the Innovation and Patient Access to Personalised Medicine workshop, organised by the European Alliance for Personalised Medicine (EAPM) in collaboration with the Irish Presidency of the European Union (EU) Council.
Breda has a wealth of experience as a patient and as a spokesperson, through her roles as a Board member for the Asthma Society of Ireland and President of EFA. As a person with severe asthma she is keen to see developments in the accessibility of personalised medicines.
At the workshop, she will discuss why a partnership between public and private organisations is needed for severe asthma, and how U-BIOPRED is tackling the challenges involved in developing personalized medicines for asthma. She will discuss headline results from the project so far and how they could impact patients. She will provide her thoughts on the reasons for U-BIOPRED’s successes and identify ways in which other scientists researching personalized medicines in other disease areas can learn from the project.
The workshop in Dublin identifies the importance of public-private partnerships as a tool for pushing forward research in personalized medicines across medical fields. The public members in these partnerships could include academics, industry, small-medium enterprises (SMEs) regulators and patients, giving scope for a great variety of organisations to offer their expertise and experience.